Canada markets closed

Curis, Inc. (CRIS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
11.86-2.45 (-17.12%)
At close: 04:00PM EST
12.46 +0.60 (+5.06%)
After hours: 07:38PM EST

Curis, Inc.

Building C
Suite 500 128 Spring Street
Lexington, MA 02421
United States
617 503 6500

Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Mr. James E. DentzerPresident, CEO & Director912.29kN/A1967
Ms. Diantha Duvall CPA, M.B.A.CFO, Treasurer, Assistant Secretary, Principal Financial Officer & Principal Accounting Officer588.95kN/A1972
Mr. Mark W. NoelVice President of Technology Management & Intellectual Property279.28k85.7k1959
Ms. Elif McDonaldVP of Investor Relations & Corporate CommunicationsN/AN/AN/A
Dr. Reinhard Wilhelm von Roemeling M.D.Senior Vice President of Clinical DevelopmentN/AN/AN/A
Dr. Jonathan B. Zung Ph.D.Chief Development OfficerN/AN/A1965
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Curis, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.